DNTH insider trading — Dianthus Therapeutics, Inc.
No open-market insider purchases or sales were filed for Dianthus Therapeutics, Inc. (DNTH) in the last 90 days. Other insider transactions — such as stock awards, option exercises or tax withholding — are listed below.
Updated Oct 16, 2026.
Recent DNTH insider transactions
Every Form 4 filed by Dianthus Therapeutics, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Carr Edward | CHIEF ACCOUNTING OFFICER | M · Option exercise · 10b5-1 | Direct | 20,000 | $17.88 | $358K | Form 4 |
| Sep 17, 2026 | Carr Edward | CHIEF ACCOUNTING OFFICER | S · Sale · 10b5-1 | Direct | 20,000 | $101.38 | $2.03M | Form 4 |
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | M · Option exercise · 10b5-1 | Direct | 23,124 | $20.63 | $477K | Form 4 |
| Sep 1, 2026 | Randhawa Simrat | EVP, Head of R&D | S · Sale · 10b5-1 | Direct | 23,124 | $106.41 | $2.46M | Form 4 |
| Aug 19, 2026 | Read Simon | Director | M · Option exercise · 10b5-1 | Direct | 2,778 | $18.36 | $51K | Form 4 |
| Aug 19, 2026 | Read Simon | Director | S · Sale · 10b5-1 | Direct | 2,778 | $117.55 | $327K | Form 4 |
| Aug 13, 2026 | Veness Adam M | SVP, General Counsel and Sec. | M · Option exercise | Direct | 15,000 | $18.17 | $273K | Form 4 |
| Aug 10, 2026 | Mcgeorge Anne | Director | M · Option exercise · 10b5-1 | Direct | 7,750 | $12.52 | $97K | Form 4 |
| Aug 10, 2026 | Mcgeorge Anne | Director | S · Sale · 10b5-1 | Direct | 7,750 | $109.01 | $845K | Form 4 |
| Aug 10, 2026 | Read Simon | Director | M · Option exercise · 10b5-1 | Direct | 2,777 | $18.36 | $51K | Form 4 |
| Aug 10, 2026 | Read Simon | Director | S · Sale · 10b5-1 | Direct | 2,777 | $109.55 | $304K | Form 4 |
| Aug 10, 2026 | Veness Adam M | SVP, General Counsel and Sec. | M · Option exercise · 10b5-1 | Direct | 16,167 | $17.88 | $289K | Form 4 |
| Aug 10, 2026 | Veness Adam M | SVP, General Counsel and Sec. | S · Sale · 10b5-1 | Direct | 16,167 | $110.38 | $1.78M | Form 4 |
| Aug 7, 2026 | Veness Adam M | SVP, General Counsel and Sec. | M · Option exercise · 10b5-1 | Direct | 3,833 | $17.88 | $69K | Form 4 |
| Aug 7, 2026 | Veness Adam M | SVP, General Counsel and Sec. | S · Sale · 10b5-1 | Direct | 3,833 | $110.70 | $424K | Form 4 |
| Aug 7, 2026 | Garcia Marino | CEO AND PRESIDENT | M · Option exercise · 10b5-1 | Direct | 166,000 | $8.44 | $1.40M | Form 4 |
| Aug 7, 2026 | Garcia Marino | CEO AND PRESIDENT | S · Sale · 10b5-1 | Direct | 166,000 | $108.11 | $17.95M | Form 4 |
DNTH insider trading FAQ
Are insiders buying DNTH stock?
Not on the open market. In the last 90 days, Dianthus Therapeutics, Inc. insiders made no open-market purchases, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading DNTH?
No insider bought or sold on the open market in the last 90 days.
Where does DNTH insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.